Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Baird

Showing results (681-690 of 784) with videos related to

Pageof 79
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast CancerErika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Environmental Science & Technology|September 30, 2021
Correlates of Persistent Endocrine-Disrupting Chemical Mixtures among Reproductive-Aged Black WomenSamantha Schildroth, Lauren A Wise, Amelia K Wesselink, et al.
JAMA Network Open|May 29, 2024
Menarche and Time to Cycle Regularity Among Individuals Born Between 1950 and 2005 in the USZifan Wang, Gowtham Asokan, Jukka-Pekka Onnela, et al.
Chemosphere|April 17, 2024
Non-persistent endocrine disrupting chemical mixtures and uterine leiomyomata in the study of environment, lifestyle and fibroids (SELF)Victoria Fruh, Amelia K Wesselink, Samantha Schildroth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
JCO Precision Oncology|November 4, 2022
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and PertuzumabStefanie Fischer, Thorsten O Götze, Aurelius Omlin, et al.
American Journal of Obstetrics and Gynecology|May 14, 2022
Attempts to conceive and the COVID-19 pandemic: data from the Apple Women's Health StudyVictoria Fruh, Genevieve Lyons, Ariel L Scalise, et al.
Hospital Pediatrics|June 22, 2026
Language-Related Safety Disparities Following a Health Literacy-Informed Rounds InterventionH Shonna Yin, Alisa Khan, Alexander F Glick, et al.
Diabetes|April 1, 1997
Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.KT M Frayling, M P Bulamn, S Ellard, et al.
American Journal of Obstetrics and Gynecology|March 12, 2025
Menstrual product use patterns in a large digital cohort in the United States: variations by sociodemographic, health, and menstrual characteristicsZifan Wang, Elizabeth Peebles, Donna D Baird, et al.
Pageof 79

Showing results (681-690 of 784) with videos related to

Sort By:
Pageof 79
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER<sup>+</sup>/HER2<sup>-</sup> Advanced Breast CancerErika P Hamilton, Manish R Patel, Anne C Armstrong, et al.
Environmental Science & Technology|September 30, 2021
Correlates of Persistent Endocrine-Disrupting Chemical Mixtures among Reproductive-Aged Black WomenSamantha Schildroth, Lauren A Wise, Amelia K Wesselink, et al.
JAMA Network Open|May 29, 2024
Menarche and Time to Cycle Regularity Among Individuals Born Between 1950 and 2005 in the USZifan Wang, Gowtham Asokan, Jukka-Pekka Onnela, et al.
Chemosphere|April 17, 2024
Non-persistent endocrine disrupting chemical mixtures and uterine leiomyomata in the study of environment, lifestyle and fibroids (SELF)Victoria Fruh, Amelia K Wesselink, Samantha Schildroth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
JCO Precision Oncology|November 4, 2022
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and PertuzumabStefanie Fischer, Thorsten O Götze, Aurelius Omlin, et al.
American Journal of Obstetrics and Gynecology|May 14, 2022
Attempts to conceive and the COVID-19 pandemic: data from the Apple Women's Health StudyVictoria Fruh, Genevieve Lyons, Ariel L Scalise, et al.
Hospital Pediatrics|June 22, 2026
Language-Related Safety Disparities Following a Health Literacy-Informed Rounds InterventionH Shonna Yin, Alisa Khan, Alexander F Glick, et al.
Diabetes|April 1, 1997
Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.KT M Frayling, M P Bulamn, S Ellard, et al.
American Journal of Obstetrics and Gynecology|March 12, 2025
Menstrual product use patterns in a large digital cohort in the United States: variations by sociodemographic, health, and menstrual characteristicsZifan Wang, Elizabeth Peebles, Donna D Baird, et al.
Pageof 79